Medsafe lets two New Zealand psychiatrists prescribe MDMA for severe PTSD

Medsafe approved two psychiatrists on 4 September to prescribe pharmaceutical-grade MDMA as part of treatment for adults with post-traumatic stress disorder. They are Dr Gary Wynn in Wellington, who works on trauma, and Dr Tom Paterson in Auckland, who works on addiction. The pair spent more than a year on the application. New Zealand is the second country to allow this use. Australia authorised psychiatrists to prescribe MDMA for PTSD in July 2023.

MDMA is not an approved medicine in New Zealand. The decision is a prescriber approval, not a product registration. Any other clinician who wants to use the drug must file a separate request. Patients must be 18 or older and pass a full clinical assessment. Treatment happens in the psychiatrist's clinic under an approved protocol. The Ministry of Health said patients will not be given MDMA to take home.

What a course looks like

A standard course is three rounds and about 54 hours of therapy. Each round is expected to cost around NZ$15,000. There is no public funding line yet. That means the first patients will pay, or will need an insurer that will accept an unapproved medicine used under a named-prescriber rule. Associate Health Minister David Seymour, who last year backed psilocybin for treatment-resistant depression, said PTSD ruins lives and is hard to treat, and that MDMA can work through psychedelic-assisted therapy.

Medsafe said it weighed the chance of benefit against harm and kept the gate narrow: two named doctors, adult patients, clinic only, case-by-case consent. The 2025 psilocybin approval for one psychiatrist set the template. Friday's decision copies that template onto a second molecule.

What the evidence still is

The ministry was plain that evidence on MDMA for PTSD is still coming in internationally. That is why the drug remains unapproved as a medicine. The Australian precedent from 2023 is the closest regulatory neighbour. It has not produced a mass prescribing market. It has produced a small number of authorised rooms and a long waiting list. New Zealand's two-clinic start will look similar.

Cocaine and MDMA sit in different legal boxes, but both are controlled. The difference that matters here is the setting. A nightclub dose and a clinic dose with a therapist in the room are not the same product in the eyes of Medsafe. The approval lives or dies on that distinction holding in practice.